Brief: Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
05/01/2022 11:36
Jan 5 (Reuters) - Progenity Inc PROG.O :
* PROGENITY ANNOUNCES ACCEPTANCE OF TWO ABSTRACTS ON
TREATMENT OF
GASTROINTESTINAL DISORDERS AT ECCO’22
Source text for Eikon: ID:nGNX2nsx24
Further company coverage: PROG.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Biora Therapeutics
See all newsBiora Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Biora Therapeutics Provides Corporate Update And Reports Third Quarter 2024 Financial Results
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Brief: Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules